Holen Sie sich die Stockscreener-App
24.12
2.20%
0.52
Vorhandelsmarkt:
24.12
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Latha Vairavan Sells 2,853 Shares - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (NASDAQ: ARQT) CFO gets RSU, option grants and sells shares - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Arcutis Biotherapeutics (ARQT) Begins Phase 1 Study of ARQ-234 - GuruFocus
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial - Investing.com
New Arcutis trial tests immune-checkpoint drug for atopic dermatitis - Stock Titan
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Targets Report: Can Arcutis Biotherapeutics Inc deliver consistent EPS growth2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Masaru Matsuda reports Rule 144 share sales for Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) insider sale notice: 3,687 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 37,349 shares after vesting - Stock Titan
Mizuho cuts Arcutis stock price target to $35 on higher costs - Investing.com UK
Arcutis Biotherapeutics (ARQT) insider sale notice: 10,000 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.9% After Analyst Downgrade - MarketBeat
ARQT: Mizuho Lowers Price Target but Maintains Outperform Rating - GuruFocus
Mizuho Has Lowered Expectations for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price - MarketBeat
Research Analysts Offer Predictions for ARQT Q1 Earnings - MarketBeat
Precision Trading with Arcutis Biotherapeutics Inc. (ARQT) Risk Zones - Stock Traders Daily
ARQT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arcutis Biotherapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-02-27 - Seeking Alpha
Arcutis execs join TD Cowen health care conference March 2-4 - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $35.00 at Guggenheim - MarketBeat
Guggenheim Raises Price Target for ARQT to $35 | ARQT Stock News - GuruFocus
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Issues Pessimistic Outlook for ARQT Earnings - MarketBeat
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - Bitget
TD Cowen Raises Target Price for Arcutis Biotherapeutics (ARQT) to $35 | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $35.00 Price Target at TD Cowen - MarketBeat
Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics - Benzinga
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case - Seeking Alpha
ARQT: HC Wainwright & Co. Raises Target Price to $34 in Latest A - GuruFocus
Needham raises Arcutis stock price target to $36 on strong sales - Investing.com Nigeria
H.C. Wainwright raises Arcutis stock price target on strong Zoryve sales - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Price Target Raised by Needham | - GuruFocus
Earnings call transcript: Arcutis Biotherapeutics Q4 2025 beats expectations By Investing.com - Investing.com Australia
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) Q4 2025 Earnings Call Highlig - GuruFocus
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates - Bitget
Arcutis Q4 2025 slides: ZORYVE drives profitability, revenue beats By Investing.com - Investing.com South Africa
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - aol.com
Earnings call transcript: Arcutis Biotherapeutics Q4 2025 beats expectations - Investing.com Nigeria
Arcutis Biotherapeutics Q4 Earnings Call Highlights - MarketBeat
Arcutis (ARQT) Exceeds Revenue Expectations with Strong Q4 Perfo - GuruFocus
Arcutis Biotherapeutics Q4 Swings to Profit, Revenue Rises; 2026 Guidance Revised - marketscreener.com
Arcutis Biotherapeutics Inc Files For Mixed Shelf - TradingView
Arcutis Biotherapeutics surges on earnings beat, raised guidance - Investing.com
Arcutis Biotherapeutics, Inc. SEC 10-K Report - TradingView
Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Earnings Results, Beats Expectations By $998.98 EPS - MarketBeat
Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q4 Revenue $129.5M, vs. FactSet Est of $113.1M - marketscreener.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):